ClinicalTrials.gg
CompletedNCT03461042BREDUpdated Nov 20, 2024

The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia

A Phase 4 interventional study of Ramelteon 8mg and Placebo in Chronic Insomnia, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, 1 of them phase 3. ramelteon · Sleep Initiation and Maintenance Disorders.

Enrollment
29th of 36
17 · median 65
Started
2018
with 1 other
Phase 4
13 of 36
none open now
Registered
34th of 36
by date

Among the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, this one is the 29th largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 4, and was the 34th registered.

Sleep Initiation and Maintenance Disorders

2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

1 of the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders is open now. Recruiting first, the newest first:

About ramelteon

ramelteon: first FDA approval 2005 (ROZEREM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

To investigate effects on combination use of Ramelteon in the dose reduction or interruption process of (non-)BZD hypnotics during the dose reduction or interruption algorithm.

Read the detailed description

The hypnotic 'Ramelteon' does not have effect on Gamma Aminobutyric Acid (GABA-A) receptor that relates to the formation of addiction to the BZD or non-BZD hypnotics. Some results of clinical trials has been reported that the dose reduction or interruption of (non-)BZD hypnotics was achieved on combination use of Ramelteon by using its characteristic of the action mechanism with safely and effectively. However, these results have not been confirmed with randomized controlled trials.

03

Conditions studied

  • Chronic Insomnia

Keywords

  • Chronic insomnia
  • Ramelteon
  • Rozerem
  • dose reduction
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting Criteria 1 or 2 and Criteria 3 and all subsequent criteria will be included in the study:

  1. Patients diagnosed as chronic insomnia having sleep onset disturbance, and with a duration of the disease of at least 6 months
  2. Patients diagnosed with chronic insomnia comorbid with mood disorders (depression or bipolar disorder) can be included to this study if they have remission of mood symptoms.
  3. Patients taking (non-)BZD hypnotics (including etizolam at bedtime) at a fixed dose in the following patterns since at least 1 month prior to consent (over 90% of drug compliance should be confirmed at the time of medical interview):

    • Patients taking 2 drugs at the usual dose (1 unit)
    • Patients taking 3 drugs at the usual dose (1 unit)
    • Patients taking 4 drugs at the usual dose (1 unit)
    • Patients taking a drug at 2-fold of the usual dose (2 units)
    • Patients taking a drug at 2-fold of the usual dose (2 units) and a drug at the usual dose (1 unit)
    • Patients taking a drug at 2-fold of the usual dose (2 units) and 2 drugs at the usual dose (1 unit)
    • Patients taking 2 drugs at 2-fold of the usual dose (2 units) Patients whose total dosage are 2~4 units of 1~4 drugs can be also included. But attention needed not to conflict with exclusion criteria 2.

      ※Dosage cannot exceeded 2 units per 1 drug.

    • Patients whose symptoms of insomnia were stabilized, and the investigators determined that the (non-) BZD hypnotics could be reduced or discontinued
    • Patients aged 20 years or older at the time of consent
    • Patients who are willing to comply with algorithm for dose reduction and discontinuation
    • Patients who can understand the content of the study and provide consent to participate in the study in writing on their own will.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria will not be included in the study:

  • Patients with secondary insomnia
  • Patients taking (non-)BZD hypnotics at a dose exceeding 2-fold of the usual dose
  • Patients taking barbiturate and non-barbiturate hypnotics and Suvorexant.
  • Patients taking hypnotics other than medicinal pharmaceuticals (including Over The Counter (OTC), supplements believed to be effective for insomnia and melatonin )
  • Patients taking mianserin hydrochloride, mirtazapine, and trazodone hydrochloride
  • Patients taking antipsychotics
  • Patients taking anxiolytic or clonazepam at bedtime

    *Patient taking anxiolytic and/or clonazepam at times except for bed-time will be included in the study. However, dosage and timing of administration can not be changed during the study period.

  • Patients who took ramelteon within 1 month prior to the
  • Patients in whom the dose of psychotropics except for the items 2~7 were changed within 1 month prior to the informed consent
  • Patients who are comorbid with depression or bipolar disordered and in whom depressive symptoms have not remitted
  • Patients in whom frequency in Q9 of PHQ "thoughts that you would be better off dead or thoughts of hurting yourself in some way" is "more than half the days (in the past 2 weeks)" or the total score is 10 or higher
  • Patients with dementia, schizophrenia, drug dependence and alcoholic
  • Patients with liver/kidney disorder, female subjects who are pregnant or in breast-feeding, and malignant neoplasm
  • Night workers
  • Patients meeting for ramelteon
  • Other patients judged ineligible for participation in the study by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Arm R

    Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.

    Drug: Ramelteon 8mg

  • Placebo comparator
    Arm PL

    Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.

    Drug: Placebo

Interventions

  • DrugRamelteonStudies of RamelteonRamelteon pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent

  • DrugPlacebo

    Placebo capsule once daily before bedtime for 12 weeks since informed consent

06

What researchers measure

Primary outcomes

  1. The achievement ratio of the 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12weeks or withdrawal without any deterioration of insomnia symptoms.

    Evaluate the achievement ratio of the 50% or more of dose reduction by Participant's diary

    Time frame: 12 weeks

  2. The rate of subjects who achieved more than 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12 weeks or withdrawal since informed consent.

    The rate of subjects who achieved more than 50% of dose reduction (Diazepam conversion value) will be assessed by Participant's diary

    Time frame: 12 weeks

Secondary outcomes

  1. The achievement ratio of the 50% dose reduction (Diazepam conversion value) at 4weeks and 8weeks

    The rate of subjects who achieved more than 50% dose reduction (Diazepam conversion value) will be assessed by Participant's diary

    Time frame: at 4 weeks and 8weeks

  2. The average of the dose reduction rate at 4weeks, 8weeks and 12weeks

    The average of the dose reduction rate will be assessed by Participant's diary

    Time frame: at 4 weeks, 8weeks and 12 weeks

  3. The achievement ratio of the 100% dose reduction at 12weeks or withdrawal

    The achievement ratio of the 100% dose reduction will be assessed by Participant's diary

    Time frame: 12 weeks

  4. The variation in total score of Pittsburg Sleep Quality Index (PSQI) at 4weeks, 8weeks and 12weeks

    The variation in total score of PSQI will be assessed by the PSQI value sets sets at week 0, 4, 8 and 12. (The range of total score is 0-21. Higher scores represent worse tendency of the symptoms.)

    Time frame: at 0, 4, 8 and 12 weeks

  5. The variation in total score of Athens Insomnia Scale (AIS) at 4weeks, 8weeks and 12weeks

    The variation in total score of AIS will be assessed by the AIS value sets at week 0, 4, 8 and 12. (The range of total score is 0-24. Higher scores represent worse tendency of the symptoms.)

    Time frame: at 0, 4, 8 and 12 weeks

  6. The variation in Patient health questionnaire (PHQ-9) score at 4weeks, 8weeks and 12weeks

    The variation in PHQ-9 score will be assessed by the PHQ-9 value sets at week 0, 4, 8 and 12. (The range of total score is 0-27. Higher scores represent worse tendency of the symptoms.)

    Time frame: at 0, 4, 8 and 12 weeks

  7. Guide to the use of the clinical withdrawal assessment scale for benzodiazepines (CIWA-B) score at 4weeks, 8weeks and 12weeks

    The variation in CIWA-B (Guide to the use of the clinical withdrawal assessment scale for benzodiazepines) score will be assessed by the CIWA-B value sets at week 4, 8 and 12. (The range of total score is 0-80. Higher scores represent worse tendency of the symptoms.)

    Time frame: at 4, 8 and 12 weeks

  8. Patient global impression of therapy (PGI) score at 12weeks or withdrawal

    PGI(Patient global impression of therapy) score will be assessed by the PGI value sets at 12weeks or withdrawal. (The range of total score is 0-21. Higher scores represent worse tendency of the symptoms.)

    Time frame: 12 weeks

  9. The variation in Ben-dep(Benzodiazepine Dependence Self-Report Questionnaire) score at 12weeks or withdrawal

    The variation in Ben-dep score will be assessed by the Ben-dep value sets at 0 and 12weeks or withdrawal. (The range of total score is 0-100. Higher scores represent worse tendency of the symptoms.)

    Time frame: at 0 and 12 weeks

  10. Adverse Events

    Adverse Events will be determined by the latest version of MedDRA/J (Medical Dictionary for Regulatory Activities/J).

    Time frame: 12 weeks

07

Study locations

1 site
  • Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science
    Shibuya-ku, Tokyo 151-0053, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2019, 17 months.

Of 52 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 17 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Mar 9, 2018
StartActual
Feb 6, 2018
Primary completionActual
Jul 31, 2019
CompletionActual
Mar 16, 2020
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03461042
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Feb 6, 2018
Primary completion
Jul 31, 2019
Completion
Mar 16, 2020
Last update
Nov 20, 2024

Study contacts

Yuichi Inoue, MD, Ph.D.
principal investigator · Yoyoghi Sleep Disorder Clinic / Foundation of Sleep and Health Science

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramelteon

Start the discussion